WO2003000729A3 - Secreted polypeptide and their use in the treatment of bone disorders - Google Patents

Secreted polypeptide and their use in the treatment of bone disorders Download PDF

Info

Publication number
WO2003000729A3
WO2003000729A3 PCT/US2001/048938 US0148938W WO03000729A3 WO 2003000729 A3 WO2003000729 A3 WO 2003000729A3 US 0148938 W US0148938 W US 0148938W WO 03000729 A3 WO03000729 A3 WO 03000729A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
bone disorders
secreted polypeptide
polypeptide
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/048938
Other languages
French (fr)
Other versions
WO2003000729A2 (en
Inventor
Audrey Goddard
William I Wood
Weilan Ye
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to AU2002229091A priority Critical patent/AU2002229091A1/en
Priority to EP01990229A priority patent/EP1397383A2/en
Publication of WO2003000729A2 publication Critical patent/WO2003000729A2/en
Publication of WO2003000729A3 publication Critical patent/WO2003000729A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a novel polypeptide and to nucleic acid molecules encoding that polypeptide. Also provided herein are methods of treating and diagnosing bone disorders.
PCT/US2001/048938 2001-06-20 2001-12-13 Secreted polypeptide and their use in the treatment of bone disorders Ceased WO2003000729A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002229091A AU2002229091A1 (en) 2001-06-20 2001-12-13 Secreted polypeptide and their use in the treatment of bone disorders
EP01990229A EP1397383A2 (en) 2001-06-20 2001-12-13 Secreted polypeptide and their use in the treatment of bone disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USPCT/US01/19692 2001-06-20
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
USPCT/US01/21735 2001-07-09
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Publications (2)

Publication Number Publication Date
WO2003000729A2 WO2003000729A2 (en) 2003-01-03
WO2003000729A3 true WO2003000729A3 (en) 2003-03-06

Family

ID=26680506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048938 Ceased WO2003000729A2 (en) 2001-06-20 2001-12-13 Secreted polypeptide and their use in the treatment of bone disorders

Country Status (3)

Country Link
EP (1) EP1397383A2 (en)
AU (1) AU2002229091A1 (en)
WO (1) WO2003000729A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (en) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
WO2000056889A2 (en) * 1999-03-23 2000-09-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000063382A1 (en) * 1999-04-15 2000-10-26 Osiris Therapeutics, Inc. Genes and expression products from hematopoietic cells
WO2001062891A2 (en) * 2000-02-24 2001-08-30 Human Genome Sciences, Inc. 207 human secreted proteins
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (en) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
WO2000056889A2 (en) * 1999-03-23 2000-09-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000063382A1 (en) * 1999-04-15 2000-10-26 Osiris Therapeutics, Inc. Genes and expression products from hematopoietic cells
WO2001062891A2 (en) * 2000-02-24 2001-08-30 Human Genome Sciences, Inc. 207 human secreted proteins
WO2002000690A2 (en) * 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 9 June 2001 (2001-06-09), KUMAR, S. ET AL: "HOA2-G-8 HOA (Human Osteoarthritic Cartilage) Homo sapiens cDNA, mRNA sequence", XP002218581, Database accession no. BG897954 *
KUMAR, S. ET AL.: "Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries.", OSTEOARTHRITIS AND CARTILAGE, vol. 9, no. 7, October 2001 (2001-10-01), pages 641 - 53, XP008009844 *

Also Published As

Publication number Publication date
EP1397383A2 (en) 2004-03-17
AU2002229091A1 (en) 2003-01-08
WO2003000729A2 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
SI1434791T1 (en) Specific binding agents of human angiopoietin-2
WO2002076494A3 (en) USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
MXPA03006321A (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists.
SG121733A1 (en) Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2001062891A3 (en) 207 human secreted proteins
AU2002340465A1 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2002004521A3 (en) Proteins with integrin-like activity
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2004089982A3 (en) April variants and methods thereof
WO1995035373A3 (en) Nucleic acid molecules encoding human contactin
EP1414863A4 (en) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2002099066A3 (en) 20 human secreted proteins
AU2002257117A1 (en) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2002057420A3 (en) 50 human secreted proteins
AU2002229091A1 (en) Secreted polypeptide and their use in the treatment of bone disorders
WO2001085903A3 (en) A novel polypeptide- human protein 9 which contains a p5cr characteristic sequence fragment and a polynucleotide encoding the same
WO2002008421A1 (en) A novel polypeptide, a human tumor necrosis factor receptor 21.45 and the polynucleotide encoding the polypeptide
WO2003038038A3 (en) 16 human secreted proteins
WO2001083677A3 (en) A novel polypeptide- human chiken limb deformity protein fh12-13 and the polynucleotide encoding said polypeptide
WO2002062845A3 (en) Adhesion molecules
WO2002010400A1 (en) A NOVEL POLYPEPTIDE- tRNA GUANINE GLYCOSYLETRANSFERASE 17.82 AND THE POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE
WO2001083758A3 (en) A novel polypeptide- human dihydroorotase 8 and the polynucleotide encoding said polypeptide
EP1392716A4 (en) Isolated human secreted proteins nucleic acid molecules encoding human secreted proteins and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001990229

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001990229

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001990229

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP